Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Pituitary Disorders
Should we be considering transsphenoidal surgical resection as first-line therapy for prolactinomas?
Wu, PMID 38253861
Answer from: at Community Practice
A dopamine agonist is the first line of treatment for prolactinomas because most patients respond well to this treatment and tolerate it.
Sign In
or
Register
to read more
25433
Related Questions
How would you manage new onset amenorrhea, diabetes insipidus and growth hormone deficiency without other pituitary deficiencies or excess in young females with MRI findings of pituitary mass and hypothalamic edema?
What degree of prolactin elevation is typically seen in patients with end stage kidney disease on hemodialysis?
In patients using NuvaRing for contraception, is the 1mg dexamethasone suppression test reliable to screen for cortisol excess?
Does hyperprolactinemia always need to be treated if the patient has regular menses, no galactorrhea, no desire for fertility and MRI of the pituitary is normal?
Do you pursue additional cardiac evaluation for patients diagnosed with Sheehan Syndrome, considering their elevated risk for atherosclerotic cardiovascular diseases?
In patients with confirmed hypercortisolism with a high/normal unsuppressed ACTH who have both a pituitary adenoma and adrenal adenoma identified on imaging, can you reliably use DHEA-S to determine the source of cortisol production?
Can the desmopressin stimulation test be used to assess for central adrenal insufficiency?
What are the advantages of oral octreotide acetate over its long acting injectable formulation for treatment of acromegaly?
Do you recommend treating a macroprolactinoma that is acutely undergoing spontaneous apoplexy with dopaminergic agents?
For non-functional pituitary macroadenomas, how effective has cabergoline been in reducing tumor size or preventing the need for surgery?